SBIR-STTR Award

Thromboresistant polyurethane cardia valve development
Award last edited on: 3/25/02

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$50,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
The late Philip Litwak

Company Information

Thoratec Corporation (AKA: Thoratec Laboratories Corporation)

6035 Stoneridge Drive
Pleasanton, CA 94588
   (925) 847-8600
   customer.service@thoratec.com
   www.thoratec.com
Location: Multiple
Congr. District: 14
County: Alameda

Phase I

Contract Number: 1R43HL040238-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1988
Phase I Amount
$50,000
A new cardiac valve fabricated from a novel polyurethane material has been fabricated and tested in vitro. These preliminary tests indicate that thi device is durable (no failures in tests lasting at least 200 million cycles) and possesses hemodynamic characteristics comparable to currently available valves.The segmented polyurethaneurea developed for this use is unique because it bulk properties, for long-term durability, and surface properties, for biocompatibility, have been separated and developed in two distinct materials. Blending of the two components results in a single material incorporating the properties of each. In vivo evaluation of rods of this material and of ventricular assist device pumping sacs has demonstrated it excellent physical and thromboresistant characteristics.We propose to fabricate valves and test them both in vitro and in vivo. Steady-state and pulsatile conditions will be used for the mock loop testing. Valves will be implanted in left ventricle to aorta shunts in calves, a model that we have used many times to evaluate other devices. Additional hemodynamic testing will be performed on explanted valves, as will SEM and X-ray analysis.National Heart, Lung and Blood Institute (NHLBI)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----